Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers

Journal of Pharmaceutical Sciences

Volumn 103, Issue 9, 2014, Pages 2937-2949

  Li, Xiaojian ^a   Vogt, Frederick G ^b   Hayes, Don ^c,d   Mansour, Heidi M ^e  

^a University of Kentucky   (United States)

^b GLAXOSMITHKLINE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

aerosols; anti infectives; confocal Raman microscopy; glass transition; lung; particle size respiratory delivery; pulmonary drug delivery; solid state particle engineering design; spray drying

Indexed keywords

AZITHROMYCIN; MANNITOL; NANOPARTICLE; TOBRAMYCIN; AEROSOL; ANTIINFECTIVE AGENT; GLASS; POWDER; SOLUTION AND SOLUBILITY;

AEROSOL; ARTICLE; DIFFRACTION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRY POWDER INHALER; GLASS TRANSITION TEMPERATURE; IN VITRO STUDY; MOLECULAR WEIGHT; PARTICLE SIZE; PHASE TRANSITION; PHYSICAL CHEMISTRY; ROOM TEMPERATURE; SPRAY DRYING; SURFACE CHARGE; WATER CONTENT; WATER VAPOR; ADMINISTRATION AND DOSAGE; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; POWDER; PROCEDURES; SOLUTION AND SOLUBILITY; TRANSITION TEMPERATURE;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; DRY POWDER INHALERS; GLASS; LUNG; MANNITOL; NANOPARTICLES; PARTICLE SIZE; POWDERS; SOLUTIONS; TRANSITION TEMPERATURE;

EID: 84906317912     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23955     Document Type: Article

References (41)

1. Katzenstein AL, Myers JL,. 1998. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157 (4 Pt 1): 1301-1315.
2. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, Murphy TF,. 2007. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176 (4): 356-361.
3. Sexauer WP, Fiel SB,. 2003. Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med 24 (6): 717-726.
4. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG,. 1991. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 337 (8738): 392-394.
5. Li X, Vogt FG, Hayes D Jr., Mansour HM,. 2014. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. J Aerosol Med Pulm Drug Deliv. [Epub ahead of print.]
6. Li X, Vogt FG, Hayes D Jr., Mansour HM,. 2014. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. Eur J Pharm Sci 52: 191-205.
7. Westmeier R, Steckel H,. 2008. Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment. J Pharm Sci 97 (6): 2299-2310.
8. Taylor RF, Morgan DW, Nicholson PS, Mackay IS, Hodson ME, Pitt TL,. 1992. Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis. Thorax 47 (6): 426-428.
9. Tiddens HA,. 2002. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 34 (3): 228-231.
10. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G,. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109 (3): 317-325.
11. Usmani OS, Biddiscombe MF, Barnes PJ,. 2005. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 172 (12): 1497-1504.
12. Stahlhofen W, Gebhart J, Heyder J,. 1980. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 41 (6): 385-398a.
13. Murray JF, Nadel JA,. 1988. Textbook of respiratory medicine. Philadelphia: Saunders. p v. <1>.
14. Raabe OG,. 1982. Comparison of the criteria for sampling 'inhalable' and 'respirable' aerosols. Ann Occup Hyg 26 (1-4): 33-45.
15. Hickey AJ, Mansour HM,. 2009. Delivery of drugs by the pulmonary route. In Modern pharmaceutics;, Florence AT, Siepmann J, Eds. New York: Taylor & Francis, pp 191-219.
16. Hickey AJ, Mansour HM,. 2008. Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. In Modified-release drug delivery technology;, Rathbone MJ, Roberts MS, Lane ME, Eds. New York: Informa Healthcare, pp 573-602.
17. Hickey AJ, Mansour HM, Martin JT, Xu Z, Smyth HDC, Mulder T, McLean R, Langridge J, Papadopoulos D,. 2007. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 96 (5): 1282-1301.
18. Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, McLean R, Langridge J, Papadopoulos D,. 2007. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci 96 (5): 1302-1319.
19. Suarez S, Hickey AJ,. 2000. Drug properties affecting aerosol behavior. Respir Care 45 (6): 652-666.
20. Wu X, Li X, Mansour HM,. 2010. Surface analytical techniques in solid-state particle characterization for predicting performance in dry powder inhalers. Kona Powder Particle J (28): 3-19.
21. Xu Z, Mansour HM, Hickey AJ,. 2011. Particle interactions in dry powder inhaler unit processes: A review. J Adhes Sci Technol 25 (4-5): 451-482.
22. Wu X, Zhang W, Hayes D Jr, Mansour HM,. 2013. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine a multifunctional particles for dry powder inhalation aerosol delivery. Int J Nanomed 8: 1-15.
23. Wu X, Hayes DJ, Zwischenberger JB, Kuhn RJ, Mansour HM,. 2013. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des Dev Ther 7: 59-72.
24. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM,. 2013. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable DPPC and DPPC:DPPE-PEG microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomed 8: 275-293.
25. Li X, Mansour HM,. 2011. Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery. AAPS PharmSciTech 12 (4): 1420-1430.
26. Park CW, Li X, Vogt FG, Hayes D Jr., Zwischenberger JB, Park ES, Mansour HM,. 2013. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm 455 (1-2): 374-392.
27. Meenach SA, Anderson KW, Hilt JZ, McGarry RC, Mansour HM,. 2013. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. European J Pharm Sci 49 (4): 699-711.
28. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM,. 2013. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomed 8: 275-293.
29. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM,. 2013. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 49 (4): 699-711.
30. Mansour HM, Zografi G,. 2007. The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. J Pharm Sci 96 (2): 377-396.
31. Mansour HM, Hickey AJ,. 2007. Raman characterization and chemical imaging of biocolloidal self-assemblies, drug delivery systems, and pulmonary inhalation aerosols. A review. AAPS PharmSciTech 8 (4):Article 99, E01-E16.
32. Park CW, Rhee YS, Vogt F, Hayes DJ, Zwischenberger JB, DeLuca PP, Mansour HM,. 2012. Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex-vivo in respiratory drug delivery. invited paper. Adv Drug Del Rev 64 ((4) Special Theme Issue-Computational and Visualization Approaches in Respiratory Delivery.): 344-356.
33. 2006. Chapter <601> Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers monograph. USP 29-NF 24 The United States Pharmacopoeia and The National Formulary: The Official Compendia of Standards. Rockville, Maryland: The United States Pharmacopeial Convention, Inc., pp 2617-2636.
34. Finlay WH. 2008. The ARLA
35. Dunbar CA, Hickey AJ, Holzner P,. 1998. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder Particle J 16: 7-45.
36. Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HD, Mulder T, McLean R, Langridge J, Papadopoulos D,. 2007. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 96 (5): 1282-1301.
37. Yu L, Milton N, Groleau EG, Mishra DS, Vansickle RE,. 1999. Existence of a mannitol hydrate during freeze-drying and practical implications. J Pharm Sci 88 (2): 196-198.
38. Dash AK, Suryanayanan R,. 1991. Solid-state properties of tobramycin. Pharm Res 8 (9): 1159-1165.
39. Odziomek M, Sosnowski TR, Gradon L,. 2012. Conception, preparation and properties of functional carrier particles for pulmonary drug delivery. Int J Pharm 433 (1-2): 51-59.
40. Imtiaz-Ul-Islam M, Langrish TAG,. 2009. Comparing the crystallization of sucrose and lactose in spray dryers. Food Bioproducts Process 87 (C2): 87-95.
41. Adi H, Young PM, Chan HK, Agus H, Traini D,. 2010. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci 40 (3): 239-247.